126 related articles for article (PubMed ID: 38447942)
21. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
Hamano I; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
World J Urol; 2019 Nov; 37(11):2365-2373. PubMed ID: 30729312
[TBL] [Abstract][Full Text] [Related]
22. Psoas mass index at the level of the third lumbar vertebra on computed tomography is a prognostic predictor for metastatic castration-sensitive prostate cancer.
Owa S; Sasaki T; Ikadai R; Tabata Y; Takeuchi Y; Nishikawa T; Kato M; Higashi S; Sugino Y; Masui S; Nishikawa K; Inoue T
Int J Clin Oncol; 2024 Jun; 29(6):840-846. PubMed ID: 38587577
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
[TBL] [Abstract][Full Text] [Related]
24. Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China.
Zhang Y; Ding L; Zheng Y; Wang K; Xia W; Wang J; Ge P
PeerJ; 2023; 11():e14500. PubMed ID: 36624752
[TBL] [Abstract][Full Text] [Related]
25. Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy.
Kadomoto S; Yaegashi H; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Nakajima K; Mizokami A
Anticancer Res; 2019 May; 39(5):2553-2559. PubMed ID: 31092452
[TBL] [Abstract][Full Text] [Related]
26. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel.
Shi X; Pei X; Fan J; Liu T; Zhang D; Yang T; Wu K; He D; Li L
Andrologia; 2021 May; 53(4):e13916. PubMed ID: 33591598
[TBL] [Abstract][Full Text] [Related]
27.
Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
[TBL] [Abstract][Full Text] [Related]
28. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Urol; 2014 Apr; 14():33. PubMed ID: 24773608
[TBL] [Abstract][Full Text] [Related]
29. Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
Nakajima K; Mizokami A; Matsuyama H; Ichikawa T; Kaneko G; Takahashi S; Shiina H; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A;
Int J Urol; 2021 Sep; 28(9):955-963. PubMed ID: 34148264
[TBL] [Abstract][Full Text] [Related]
30. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
[TBL] [Abstract][Full Text] [Related]
31. The slope associated with nadir prostate-specific antigen is prognostically significant in men with hormone-sensitive prostate cancer after primary androgen deprivation therapy.
Zhenhao Z; Xiaofeng C; Hao J; Ming Y; Hongtao Z; Wenrui H; Cheng Z; Xiaochen Z; Gongxian W
Cancer Med; 2022 Sep; 11(17):3251-3259. PubMed ID: 35307955
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
[TBL] [Abstract][Full Text] [Related]
33. The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.
Iacovelli R; Ciccarese C; Caffo O; De Giorgi U; Basso U; Tucci M; Mosillo C; Maruzzo M; Maines F; Casadei C; Milella M; Tortora G
Anticancer Res; 2022 Jan; 42(1):165-172. PubMed ID: 34969722
[TBL] [Abstract][Full Text] [Related]
34. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer.
Mitsui Y; Shiina H; Yamamoto Y; Haramoto M; Arichi N; Yasumoto H; Kitagaki H; Igawa M
BJU Int; 2012 Dec; 110(11 Pt B):E628-34. PubMed ID: 22788759
[TBL] [Abstract][Full Text] [Related]
35. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
36. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
[TBL] [Abstract][Full Text] [Related]
37. Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.
Reza M; Jones R; Aspegren J; Massard C; Mattila L; Mustonen M; Wollmer P; Trägårdh E; Bondesson E; Edenbrandt L; Fizazi K; Bjartell A
Eur Urol Focus; 2016 Dec; 2(5):547-552. PubMed ID: 28723521
[TBL] [Abstract][Full Text] [Related]
38. Lutetium-177-PSMA-617 radioligand therapy in patients with high volume metastatic prostate cancer prior to chemotherapy and new generation androgen deprivation therapy: Clinical Experience.
Celen YZ; Elboga U; Sahin E; Kus T; Okuyan M; Cayirli YB; Erturhan S; Cimen U
Hell J Nucl Med; 2023; 26(3):187-193. PubMed ID: 38085834
[TBL] [Abstract][Full Text] [Related]
39. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Chowdhury S; Bjartell A; Agarwal N; Chung BH; Given RW; Pereira de Santana Gomes AJ; Merseburger AS; Özgüroğlu M; Juárez Soto Á; Uemura H; Ye D; Brookman-May SD; Londhe A; Bhaumik A; Mundle SD; Larsen JS; McCarthy SA; Chi KN
Ann Oncol; 2023 May; 34(5):477-485. PubMed ID: 36858151
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a novel risk model in newly diagnosed
Zhang Y; Wang J; Ding L; Zheng Y; Wu C; Wang K; Xia W; Ge P
PeerJ; 2023; 11():e14615. PubMed ID: 36650836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
